Brown A J, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E
Renal Division, Washington University School of Medicine, St. Louis, Missouri 63110.
Endocrinology. 1993 Sep;133(3):1158-64. doi: 10.1210/endo.133.3.8396012.
22-Oxacalcitriol (OCT) is one of several new analogs of vitamin D that retain many of the therapeutically useful properties of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], but have much less calcemic activity. In the present study we examined the actions of OCT on intestinal calcium absorption and calbindin D9k mRNA in vitamin D-deficient rats. After ip injection of OCT (1 microgram/kg), calcium absorption increased significantly by 2 h and was maximal at 4 h (2.5-fold above control), but returned to pretreatment levels by 16 h. In contrast, the same dose of 1,25-(OH)2D3 caused a 3-fold increase in calcium absorption, which lasted more than 48 h. The transient effect of OCT on calcium absorption was also observed when the analog was infused at a dose of 1 micrograms/kg.day for 3 days. At the end of the infusion period, calcium absorption was 3-fold higher than that in vehicle-infused controls, but fell to pretreatment levels by 24 h after removing the minipumps. The time courses for induction of calbindin D9k mRNA were similar for OCT and 1,25-(OH)2D3, with no change observed until more than 4 h after injection. However, calbindin mRNA levels returned to pretreatment values more rapidly in the OCT-treated rats. Consistent with these findings, we observed that a 1 microgram/kg dose of [3H] OCT was completely cleared by 4-6 h after injection. This was paralleled by a loss of [3H]OCT associated with the intestinal vitamin D receptor. The rapid clearance of OCT is probably due to its low affinity for the serum vitamin D-binding protein. This low affinity would also be expected to allow greater accessibility to target cells. In support of this, we found that higher amounts of OCT than 1,25-(OH)2D3 were associated with the intestinal vitamin D receptor after the injection of several doses of these tritiated ligands. In summary, our results indicate that the pharmacokinetic properties of OCT are responsible at least in part for its low calcemic activity. Furthermore, comparison of the transient elevation of calcium absorption by OCT with its more prolonged effects on PTH and calbindin D9k indicates that each action of vitamin D compounds has a distinct biological half-life. The short circulating half-life of OCT can exploit these differences to provide a therapeutic advantage in the treatment of vitamin D-responsive diseases.
22-氧杂骨化三醇(OCT)是维生素D的几种新类似物之一,它保留了1,25-二羟基维生素D3[1,25-(OH)2D3]的许多治疗有用特性,但血钙活性低得多。在本研究中,我们研究了OCT对维生素D缺乏大鼠肠道钙吸收和钙结合蛋白D9k mRNA的作用。腹腔注射OCT(1微克/千克)后,钙吸收在2小时时显著增加,并在4小时时达到最大值(比对照高2.5倍),但在16小时时恢复到预处理水平。相比之下,相同剂量的1,25-(OH)2D3使钙吸收增加了3倍,持续超过48小时。当以1微克/千克·天的剂量输注该类似物3天时,也观察到OCT对钙吸收的短暂作用。在输注期结束时,钙吸收比输注载体的对照组高3倍,但在移除微型泵后24小时降至预处理水平。OCT和1,25-(OH)2D3诱导钙结合蛋白D9k mRNA的时间进程相似,直到注射后4小时以上才观察到变化。然而,在OCT处理的大鼠中,钙结合蛋白mRNA水平恢复到预处理值的速度更快。与这些发现一致,我们观察到注射后4-6小时,1微克/千克剂量的[3H]OCT被完全清除。这与肠道维生素D受体相关的[3H]OCT的丧失平行。OCT的快速清除可能是由于其对血清维生素D结合蛋白的低亲和力。这种低亲和力也有望使它更容易接近靶细胞。支持这一点的是,在注射几剂这些氚标记配体后,我们发现与肠道维生素D受体相关的OCT比1,25-(OH)2D3更多。总之,我们的结果表明,OCT的药代动力学特性至少部分地导致了其低血钙活性。此外,将OCT引起的钙吸收短暂升高与其对甲状旁腺激素和钙结合蛋白D9k的更持久作用进行比较表明,维生素D化合物的每种作用都有不同的生物学半衰期。OCT的短循环半衰期可以利用这些差异,在治疗维生素D反应性疾病中提供治疗优势。